PO.MCB08.05 · 分子与细胞生物学

基因组一致性模式可区分多原发肿瘤与转移性复发

Genomic Concordance Patterns Distinguish Multiple Primary Tumors from Metastatic Recurrences

海报缩略图:基因组一致性模式可区分多原发肿瘤与转移性复发
编号 7273 展板 13 时间 4/22 09:00–12:00 区域 Section 21 主讲 Samuel Rivero-Hinojosa, PhD
分会场 Genomic Approaches to Define Tumor Biology and Clinical Stratification
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Brandie Taylor, Samuel Rivero-Hinojosa, Sandro Satta, Nicole Scott, Faraz Salmasi, Kevin Manage, Stephanie Woods, Charuta C. Palsuledesai, Ekaterina Kalashnikova, Angel Augusto Rodriguez, Minetta C. Liu

Oncology, Natera, Inc., Austin, TX

摘要 Abstract

中文摘要
背景 多原发癌(MPC)是指同一患者(pt)体内存在两个或以上、位于相同或不同器官的同时性或异时性恶性肿瘤,在约10-25%的癌症患者中可观察到。区分MPC与转移性疾病对分期、治疗选择和预后具有重要意义。在此,我们评估了已知患有MPC和转移性复发(MR)患者肿瘤组织的全外显子组测序(WES)数据。 方法 对来自76例MPC患者的成对不同原发肿瘤,以及来自134例MR患者的原发/转移部位肿瘤对进行比较。肿瘤组织WES作为商业化循环肿瘤DNA检测(Signatera™,Natera公司)或Altera™综合基因组分析(Natera公司)的一部分进行。为实现肿瘤间比较,归一化处理包括将变异限制在共享基因组区域内(由BED文件定义),并根据各样本各自的中位数对变异等位基因频率进行归一化。一致性分析包括共享变异(Jaccard指数)、VAF相关系数、TMB比较(mut/Mb)和单碱基置换(SBS)突变谱。离群配对通过TMB差异>5 mut/Mb或Pearson VAF相关系数<0.3来识别。 结果 MPC和MR队列的男性比例分别为44.7%和48.9%;中位患者年龄分别为69岁(40-90岁)和72岁(39-90岁)。没有任何原发肿瘤对来自同一器官。MPC肿瘤对表现出极少的体细胞突变重叠[中位Jaccard指数=0.00(0.00-0.43)],仅5%的患者有>1个共享驱动突变。近77%(59/76)的MPC肿瘤对TMB差异>2倍。此外,MPC肿瘤对之间SBS突变谱的余弦相似度分布宽泛且相对较低[中位:0.49(0-0.95)],提示存在不同的致突变过程。相比之下,MR肿瘤对表现出明显更高的基因组相似性,共享突变比例高[中位Jaccard指数=0.352(0-0.965)],共享突变中VAF相关性高(平均Pearson r=0.62),61.9%的肿瘤对具有>1个共享驱动突变。此外,MR的SBS突变谱余弦相似度呈现明显右偏分布[中位:0.77(0-0.98)]。MR配对肿瘤间的TMB大体一致,尽管15%的配对表现出>5 mut/Mb的差异。 结论 MPC和MR肿瘤对表现出明显不同的基因组一致性模式。MPC肿瘤突变共享程度低,突变谱相似性极小,提示独立的致突变过程。相反,MR肿瘤在所有基因组指标上均表现出高度的克隆连续性,提示同一起源。VAF相关性和突变特征分析提供了一个稳健的框架,可从分子水平区分MPC与MR,满足了肿瘤分类和精准肿瘤学中一项关键的未满足需求。
查看英文原文 English abstract
Background Multiple primary cancers (MPC), wherein two or more synchronous or metachronous malignant tumors in the same or different organs are present within a single patient (pt), are observed in ~10-25% of pts with cancer. Differentiating MPCs from metastatic disease has implications for staging, treatment selection and prognosis. Here, we evaluated whole exome sequencing (WES) data of tumor tissues from pts known to have MPCs and metastatic recurrence (MR). Methods Pairs of distinct primary tumors from 76 pts with MPCs and primary/metastatic site tumor pairs from 134 pts with MR were compared. Tumor tissue WES was performed as part of either commercial circulating tumor DNA testing (Signatera TM , Natera, Inc) or Altera TM Comprehensive Genomic Profiling (Natera, Inc). To enable intertumor comparison, normalization involved restricting variants to shared genomic regions (defined by a BED file) and normalizing variant allele frequencies in each sample by their respective median. Concordance analyses included shared variants (Jaccard index), VAF correlation coefficients, TMB comparisons (mut/Mb) and single-base substitution (SBS) mutational profile. Outlier pairs were identified by >5 mut/Mb TMB difference or Pearson VAF correlation <0.3. Results MPC and MR cohorts had 44.7% and 48.9% males, respectively; median pt ages were 69 (40-90) years and 72 (39-90) years, respectively. No primary tumor pairs were from the same organ. MPC tumor pairs exhibited minimal somatic mutation overlap [median Jaccard index = 0.00 (0.00-0.43)], with only 5% of patients having >1 shared driver mutations. Nearly 77% (59/76) MPC tumor pairs had >2-fold differences in TMB. Additionally, the cosine similarity distribution of SBS mutational profiles across MPC tumor pairs was broad and relatively low [median: 0.49 (0-0.95)], indicating distinct mutagenic processes. In contrast, MR tumor pairs demonstrated markedly higher genomic similarity, with high proportion of shared mutations [median Jaccard index = 0.352 (0- 0.965)], high VAF correlations (mean Pearson r = 0.62) in shared mutations, and >1 shared driver mutations in 61.9% of tumor pairs. Further, MR presented a strongly right-skewed distribution of SBS mutational profiles cosine similarity [median: 0.77 (0-0.98)]. TMB was largely concordant between MR paired tumors, though 15% of pairs exhibited divergence >5 mut/Mb. Conclusions MPC and MR tumor pairs showed markedly distinct patterns of genomic concordance. MPC tumors have low mutation sharing and minimal similarity in mutational profiles, suggesting independent mutagenic processes. Conversely, MR tumors display high clonal continuity across all genomic metrics, indicating a shared origin. VAF correlation and mutational signature profiling provides a robust framework to molecularly distinguish MPCs from MR, addressing a critical unmet need in tumor classification and precision oncology.
利益披露 Disclosure
B. Taylor, Natera, Inc. Employment, Stock, Travel. S. Rivero-Hinojosa, Natera, Inc. Employment, Stock, Travel. S. Satta, Natera, Inc. Employment, Stock, Stock Option. N. Scott, Natera, Inc. Employment, Stock, Travel. F. Salmasi, Natera, Inc. Employment, Stock, Travel. K. Manage, Natera, Inc. Employment, Stock, Travel. S. Woods, Natera, Inc. Employment, Stock, Travel. C. C. Palsuledesai, Natera, Inc. Employment, Stock, Travel. E. Kalashnikova, Natera, Inc. Employment, Stock, Travel. A. A. Rodriguez, Natera, Inc. Employment, Stock, Travel. M. C. Liu, Natera, Inc. Employment, Stock, Travel.

← 返回 AACR 2026 检索